Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RDHL 
Redhill Biopharma Ltd (RDHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.92% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.62M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 121667 | Beta 3.83 | 52 Weeks Range 2.47 - 20.27 | Updated Date 04/1/2025 |
52 Weeks Range 2.47 - 20.27 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -302.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -328.46% |
Management Effectiveness
Return on Assets (TTM) -44.88% | Return on Equity (TTM) -1708.61% |
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value -3264559 | Price to Sales(TTM) 0.98 |
Enterprise Value -3264559 | Price to Sales(TTM) 0.98 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 1298660 | Shares Floating 11112341049 |
Shares Outstanding 1298660 | Shares Floating 11112341049 | ||
Percent Insiders - | Percent Institutions 6.77 |
Analyst Ratings
Rating 5 | Target Price 40 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Redhill Biopharma Ltd
Company Overview
History and Background
Redhill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. Founded in 2009, it develops and commercializes therapies. RedHill has grown through acquisitions and internal development, focusing on niche markets with unmet needs.
Core Business Areas
- Gastrointestinal Diseases: RedHill's primary focus is developing and commercializing therapies for gastrointestinal diseases, including acute gastroenteritis and inflammatory bowel diseases (IBD).
- Infectious Diseases: The company has also explored therapies for infectious diseases such as COVID-19, seeking to leverage its existing platform for broader applications.
Leadership and Structure
RedHill Biopharma has a leadership team composed of experienced pharmaceutical executives. Its organizational structure is typical of a small to mid-sized biopharmaceutical company, with departments focused on R&D, clinical development, commercial operations, and finance. CEO is Dror Ben-Asher.
Top Products and Market Share
Key Offerings
- Talicia: Talicia is an oral capsule for the treatment of Helicobacter pylori (H. pylori) infection. Market share data is not readily available. Competitors include standard triple therapy regimens, clarithromycin-based therapies, and bismuth-based therapies.
- Movantik: Movantik (naloxegol) is a peripherally acting mu-opioid receptor antagonist (PAMORA) for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. RedHill acquired U.S. rights to Movantik from Norgine B.V.. Competitors include other PAMORAs like Relistor (methylnaltrexone) and Amitiza (lubiprostone).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The gastrointestinal disease market is growing due to factors such as aging populations, changing lifestyles, and increasing prevalence of chronic diseases.
Positioning
RedHill Biopharma focuses on niche markets and unmet needs within the gastrointestinal and infectious disease spaces. Its competitive advantage lies in its ability to develop and commercialize specialized therapies.
Total Addressable Market (TAM)
The TAM for gastrointestinal disease therapies is estimated to be in the billions of dollars. RedHill's positioning in specific niches, such as H. pylori infection and opioid-induced constipation, allows it to capture a portion of this TAM. Specific TAM estimates are constantly changing and influenced by research and market forces.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio in gastrointestinal diseases
- Established commercial infrastructure
- Experienced management team
- Proprietary technologies and formulations
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a small number of key products
- Vulnerability to generic competition
- History of net losses.
Opportunities
- Expansion into new geographic markets
- Development of new therapies for unmet needs in gastrointestinal diseases
- Acquisition of complementary products or technologies
- Strategic partnerships with larger pharmaceutical companies
Threats
- Competition from larger pharmaceutical companies with greater resources
- Generic erosion of key products
- Regulatory hurdles and delays in product approvals
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- HLX (Halozyme Therapeutics)
- AGN (Allergan, now part of AbbVie ABBV)
- IMNP (Imunomedics, now part of Gilead Sciences GILD)
Competitive Landscape
RedHill Biopharma faces competition from larger pharmaceutical companies with greater resources and established market presence. Its ability to compete depends on its specialized product portfolio and focus on niche markets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: RedHill Biopharma's growth has been driven by acquisitions and internal development of new therapies. The historical growth trajectory has been volatile.
Future Projections: Future growth depends on successful commercialization of existing products, approval of new therapies, and strategic acquisitions or partnerships. Analyst estimates vary based on market conditions and company performance.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Talicia and Movantik, as well as advancing clinical development programs.
Summary
RedHill Biopharma is a niche biopharmaceutical company with a focus on gastrointestinal diseases. Its strengths lie in its specialized product portfolio and experienced management team. However, the company faces challenges related to limited financial resources and competition from larger players. Future success depends on successful commercialization of its products and strategic partnerships.
Similar Companies
- HLX
- ABBV
- GILD
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is approximate and may vary depending on the source. Financial data is subject to change and should be verified independently.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Redhill Biopharma Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-01-07 | Co-Founder, Chairman & CEO Mr. Dror Ben-Asher | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 53 | Website https://www.redhillbio.com |
Full time employees 53 | Website https://www.redhillbio.com | ||
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.